Glucose Metabolism Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GLC008 MIFTS: 39	Glucose Metabolism Disease Categories: Genetic diseases, Metabolic diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Glucose Metabolism Disease

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease ¹¹ ¹⁴ ¹⁶

Glucose Metabolism Disorders ⁴³ ⁷¹

Disorder of Glucose Metabolism ¹¹

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4194

MeSH ⁴³ D044882

NCIt ⁴⁹ C53655

SNOMED-CT ⁶⁸ 126877002

EFO ¹⁶ EFO_0009406

UMLS ⁷¹ C1257958

Sources

Summaries for Glucose Metabolism Disease

MalaCards based summary: Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus and prediabetes syndrome. An important gene associated with Glucose Metabolism Disease is PINK1-AS (PINK1 Antisense RNA), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involvement in the immune response in sepsis. The drugs Insulin glargine and Lopinavir have been mentioned in the context of this disorder. Affiliated tissues include liver, spinal cord and endothelial.

Sources

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)

#	Related Disease	Score	Top Affiliating Genes
1	diabetes mellitus	32.6	SERPINA3 MIR29A MIR223 MIR210 MIR21 MIR17
2	prediabetes syndrome	32.6	MIR29A MIR21 MIR126 INS GCG
3	type 2 diabetes mellitus	31.5	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
4	carbohydrate metabolic disorder	31.1	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
5	body mass index quantitative trait locus 11	31.1	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
6	non-alcoholic fatty liver disease	30.9	MIR21 MIR17 MIR140 MIR126 INS GCG
7	myeloma, multiple	30.9	MIR21 MIR199A1 MIR17 MIR155 MIR142 MIR140
8	respiratory failure	30.8	SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR146A
9	lipid metabolism disorder	30.8	SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR144
10	esophageal cancer	30.8	MIR423 MIR29A MIR223 MIR21 MIR199A1 MIR17
11	overnutrition	30.8	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
12	lipoprotein quantitative trait locus	30.8	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
13	hepatocellular carcinoma	30.8	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
14	microvascular complications of diabetes 5	30.8	MIR223 MIR21 MIR199A1 MIR17 MIR126 INS
15	alcohol use disorder	30.7	SERPINA3 MIR29A MIR199A1 INS H2AC18 CCR6
16	allergic disease	30.7	SERPINA3 MIR21 MIR155 ICOSLG H2AC18 CCR6
17	adrenal gland disease	30.6	MIR210 INS CCR6
18	mild cognitive impairment	30.6	SERPINA3 MIR142 INS
19	phosphoglycerate kinase 1 deficiency	11.1
20	hypoglycemia	11.1
21	autoimmune disease of gastrointestinal tract	10.7	SERPINA3 MIR223 MIR21 MIR199A1 MIR142 MIR126
22	muscle tissue disease	10.7	SERPINA3 MIR21 MIR199A1 MIR142 MIR140 MIR126
23	muscular disease	10.7	SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR140
24	integumentary system disease	10.7	SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
25	extrinsic cardiomyopathy	10.7	SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
26	leukocyte disease	10.7	SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
27	myopathy	10.7	SERPINA3 MIR423 MIR21 MIR199A1 MIR142 MIR140
28	ovary epithelial cancer	10.7	SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR140
29	pancreatic ductal adenocarcinoma	10.7	SERPINA3 MIR223 MIR210 MIR21 MIR199A1 MIR17
30	lysosomal storage disease	10.7	SERPINA3 MIR423 MIR29A MIR21 MIR199A1 MIR17
31	dilated cardiomyopathy	10.7	SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
32	bone inflammation disease	10.7	SERPINA3 MIR29A MIR223 MIR210 MIR21 MIR199A1
33	lung disease	10.7	SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
34	skin disease	10.7	SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
35	peripheral nervous system neoplasm	10.7	SERPINA3 MIR29A MIR21 MIR199A1 MIR17 MIR144
36	pulmonary disease, chronic obstructive	10.7	SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR144
37	bone disease	10.7	SERPINA3 MIR223 MIR210 MIR21 MIR199A1 MIR17
38	heart conduction disease	10.7	SERPINA3 MIR423 MIR223 MIR21 MIR199A1 MIR17
39	disease of mental health	10.7	SERPINA3 MIR29A MIR223 MIR21 MIR199A1 MIR17
40	demyelinating disease	10.7	SERPINA3 MIR223 MIR21 MIR155 MIR146A MIR142
41	autoimmune disease of skin and connective tissue	10.7	SERPINA3 MIR223 MIR21 MIR17 MIR155 MIR146A
42	heart valve disease	10.7	SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
43	interstitial lung disease	10.7	SERPINA3 MIR29A MIR223 MIR21 MIR199A1 MIR155
44	malignant exocrine pancreas neoplasm	10.7	SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR144
45	autoimmune disease of musculoskeletal system	10.7	SERPINA3 MIR423 MIR223 MIR210 MIR21 MIR199A1
46	autonomic nervous system neoplasm	10.7	MIR29A MIR21 MIR199A1 MIR17 MIR144 MIR142
47	chromosomal disease	10.7	SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR155
48	biliary tract disease	10.7	SERPINA3 MIR29A MIR21 MIR199A1 MIR17 MIR144
49	physical disorder	10.7	SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR146A
50	bile duct disease	10.7	SERPINA3 MIR29A MIR21 MIR199A1 MIR17 MIR144

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:

Sources

Symptoms & Phenotypes for Glucose Metabolism Disease

Sources

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Insulin glargine

Approved

Phase 4

160337-95-1

118984454

Lopinavir

Approved

Phase 4

192725-17-0

92727

Lamivudine

Approved, Investigational

Phase 4

134678-17-4

60825

Zidovudine

Approved

Phase 4

30516-87-1

35370

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Pitavastatin

Approved

Phase 4

147511-69-1

5282452

Diazoxide

Approved

Phase 4

364-98-7

3019

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Iron

Approved

Phase 4

7439-89-6

29936

Anti-Infective Agents

Phase 4

Black Currant

Phase 4

Antiviral Agents

Phase 4

HIV Protease Inhibitors

Phase 4

protease inhibitors

Phase 4

Anti-Retroviral Agents

Phase 4

Lamivudine, zidovudine drug combination

Phase 4

Anti-HIV Agents

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Reverse Transcriptase Inhibitors

Phase 4

Antihypertensive Agents

Phase 4

Vasodilator Agents

Phase 4

Hormones

Phase 4

Calcium, Dietary

Phase 4

Pharmaceutical Solutions

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Ramipril

Approved

Phase 3

87333-19-5

5362129

Acarbose

Approved, Investigational

Phase 3

56180-94-0

441184 444254

Glucagon

Approved

Phase 3

16941-32-5

16133228 16186314

Aluminum sulfate

Approved

Phase 3

10043-01-3

Aluminum hydroxide

Approved, Investigational

Phase 3

21645-51-2

Tirzepatide

Approved, Investigational

Phase 3

2023788-19-2

156588324

Dulaglutide

Approved, Investigational

Phase 3

923950-08-7

Dapagliflozin

Approved

Phase 3

461432-26-8

9887712

Metformin

Approved

Phase 3

1115-70-4, 657-24-9

4091

Linagliptin

Approved

Phase 3

668270-12-0

57389748 10096344

Rosiglitazone

Approved, Investigational

Phase 3

122320-73-4, 155141-29-0

77999

Fenofibrate

Approved

Phase 3

49562-28-9

3339

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

L-Glutamine

Approved, Investigational, Nutraceutical

Phase 3

56-85-9

5961

Gastric inhibitory polypeptide

Investigational

Phase 3

100040-31-1

2,4-thiazolidinedione

Investigational

Phase 3

2295-31-0

5437

Angiotensin-Converting Enzyme Inhibitors

Phase 3

Trace Elements

Phase 3

Micronutrients

Phase 3

Glucagon-Like Peptide 1

Phase 3

Adjuvants, Immunologic

Phase 3

Calciferol

Phase 3

Immunologic Factors

Phase 3

Interventional clinical trials:

(show top 50) (show all 185)

#	Name	Status	NCT ID	Phase	Drugs
1	Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - SGLT2 Subprotocol	Unknown status	NCT04242758	Phase 4	Dapagliflozin 10 MG;Hydrochlorothiazide 12.5mg
2	Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study	Completed	NCT02689765	Phase 4
3	One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements	Completed	NCT00483769	Phase 4	Glargine
4	A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism	Completed	NCT00192621	Phase 4	Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr])
5	Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance	Completed	NCT00108615	Phase 4	Metformin;Pioglitazone
6	Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial	Recruiting	NCT04945122	Phase 4	Pitavastatin;Atorvastatin
7	Comparison of Oral Semaglutide With Matched Oral Semaglutide Placebo as an Early Treatment for Latino Adults With Type 2 Diabetes Receiving Enhanced Lifestyle Care	Recruiting	NCT04938388	Phase 4	Semaglutide Pill
8	The Impact of Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in Short-term Intensive Insulin Therapy(SIIT)	Recruiting	NCT05084079	Phase 4	CSII with formula-based initial insulin regimen;CSII with weight-based initial insulin regimen
9	Central Mechanisms That Regulate Glucose Metabolism in Humans	Active, not recruiting	NCT01028846	Phase 4	Diazoxide;Placebo
10	A 24-week, Multi-center, Randomized, Open-Label Clinical Trial to Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME Study)	Not yet recruiting	NCT05238012	Phase 4	Xuezhikang Capsule;Atorvastatin Calcium Tablets
11	A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age.	Terminated	NCT03191201	Phase 4	Ferric Carboxymaltose;0.9% sodium chloride solution
12	Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance	Withdrawn	NCT00306826	Phase 4	pioglitazone;simvastatin;pioglitazone + simvastatin
13	The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial	Completed	NCT00095654	Phase 3	Ramipril;Rosiglitazone
14	Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study)	Completed	NCT00221156	Phase 3	Acarbose
15	A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.	Completed	NCT00362323	Phase 3	fenofibrate (F) + metformin (M) hydrochloride fixed combination;Metformin
16	A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.	Completed	NCT00349128	Phase 2, Phase 3	fenofibrate and metformin combination (drug)
17	An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia	Completed	NCT00348725	Phase 3	fenofibrate and metformin fixed combination (drug)
18	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both	Recruiting	NCT05260021	Phase 3	Tirzepatide Dose 1;Tirzepatide Dose 2;Placebo
19	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype	Recruiting	NCT05018585	Phase 3
20	A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)	Active, not recruiting	NCT04809220	Phase 3	Dulaglutide;Biguanide (BG);Sulfonylurea (SU);Alpha-Glucosidase Inhibitors (α-GI);Thiazolidinedione (TZD);Glinides (GLN);Sodium-glucose cotransporter type 2 inhibitors (SGLT2i)
21	A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Study to Evaluate the Efficacy and Safety of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin	Not yet recruiting	NCT05505994	Phase 3	DWP16001;Dapagliflozin;DWP16001 Placebo;Dapagliflozin Placebo
22	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Terminated	NCT04371978	Phase 3	Linagliptin 5 MG
23	Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation	Terminated	NCT00935766	Phase 3	Omega-3;Placebo
24	A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia	Terminated	NCT00361868	Phase 3	fenofibrate (F) + metformin (M) hydrochloride fixed combination;Rosiglitazone
25	Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes	Unknown status	NCT03682640	Phase 2	Azithromycin Monohydrate;Insulin Lispro
26	Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus	Completed	NCT02644759	Phase 1, Phase 2
27	Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose.	Completed	NCT02102737	Phase 2	6-DIG
28	Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes	Completed	NCT01935804	Phase 2	Pioglitazone;Metformin
29	A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes	Completed	NCT03345004	Phase 2
30	Acute Metabolic Effects of Melatonin Treatment	Completed	NCT03204877	Phase 1, Phase 2	Melatonin
31	An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes	Completed	NCT01778348	Phase 2
32	Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans	Completed	NCT03486223	Phase 2	GSK2256294;Placebo oral capsule
33	IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes	Recruiting	NCT04227769	Phase 2	Anakinra Prefilled Syringe
34	Glucose Metabolism in South Asian Women With IGT or IFG. DIAbetes in South Asians - DIASA 3: A 12-week Intervention Trial With Oral Antidiabetic Medication to Improve Hepatic and Whole Body Insulin Sensitivity	Recruiting	NCT04662866	Phase 2	Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg
35	OsteoPreP: The Effect of Probiotic Supplementation on Bone, Muscle, and Glucose Metabolism in Postmenopausal Women: A Randomised Placebo-controlled Trial	Recruiting	NCT05348694	Phase 1, Phase 2
36	Regulation of Endogenous Glucose Production by Central KATP Channels	Recruiting	NCT03540758	Phase 2	Diazoxide;Nicotinic acid;Placebo
37	Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)	Active, not recruiting	NCT03181399	Phase 2	Triheptanoin
38	Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide	Active, not recruiting	NCT03566511	Phase 2	Diazoxide;Placebo
39	An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)	Not yet recruiting	NCT05565248	Phase 1, Phase 2
40	A Double-Blind, Placebo-Controlled, Cross-over Trial, Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults	Not yet recruiting	NCT04824872	Phase 2	Dasiglucagon;Placebo
41	The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients	Suspended	NCT03685773	Phase 2	Diazoxide;Placebo (for diazoxide);Nicotinic acid
42	Metabolic Effects of Melatonin Treatment	Completed	NCT03859934	Phase 1	Melatonin;Placebo Oral Tablet
43	Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism	Completed	NCT01103245	Phase 1	Hydrochlorothiazide (HCTZ);Aliskiren 150 mg (ALI 150);Spironolactone (SPL 25);Aliskiren 300 mg (ALI 300);Spironolactone 50 mg (SPL 50)
44	A Phase 1 Placebo-Controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Food Effect of Single Escalating Oral Doses of PF-04991532 in Healthy Adult Subjects	Completed	NCT01102673	Phase 1	PF-04991532;Placebo
45	A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)	Completed	NCT01129258	Phase 1	PF-04991532;Placebo
46	A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Dose Escalation Study In Japanese Healthy Subjects, And Open Label, Single Dose Study In Western Healthy Subjects To Investigate The Safety, Tolerability, And Pharmacokinetics of PF-04991532.	Completed	NCT01369277	Phase 1	PF-04991532;Placebo
47	A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 In Otherwise Healthy Overweight And Obese Subjects	Completed	NCT01757756	Phase 1	Pf-05175157;placebo;midazolam
48	A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus	Completed	NCT01301456	Phase 1
49	An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)	Recruiting	NCT05210530	Phase 1
50	Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial	Active, not recruiting	NCT03041363	Phase 1	Triheptanoin

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Sources

Genetic Tests for Glucose Metabolism Disease

Sources

Anatomical Context for Glucose Metabolism Disease

Organs/tissues related to Glucose Metabolism Disease:

MalaCards : Liver, Spinal Cord, Endothelial, Cortex, Brain, Colon, Heart

Sources

Publications for Glucose Metabolism Disease

Articles related to Glucose Metabolism Disease:

(show top 50) (show all 70)

#	Title	Authors	PMID	Year
1	Re-interpretation of the mechanism of type 2 diabetes mellitus based on a framework of psychosomatic medicine: a real-world study. ⁶²	Min W...Sun X	36348380	2022
2	Smoking causes the disorder of glucose metabolism under different levels of blood pressure in male occupational population. ⁶²	Wang D...Xiang Q	35942933	2022
3	Metabolites of Gut Microbiota and Possible Implication in Development of Diabetes Mellitus. ⁶²	Guo Z...Chen ZY	35549332	2022
4	Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice. ⁶²	Wang Y...Ren L	35246007	2022
5	Glucose Counteracts Isoprenaline Effects on Ion Channel Functions in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. ⁶²	Qiao L...Akin I	35323624	2022
6	Glucose Metabolism Intervention-Facilitated Nanomedicine Therapy. ⁶²	Li Z...Guan W	35747168	2022
7	Non-Alcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Developing New-Onset Diabetes After Acute Pancreatitis: A Multicenter Retrospective Cohort Study in Chinese Population. ⁶²	Lv Y...Li L	35692404	2022
8	Observation of Curative Effect of Trimetazidine Combined with Metoprolol in Elderly Patients with Coronary Heart Disease Complicated with Heart Failure and the Effect of Myocardial Remodeling by Integrated Traditional Chinese and Western Medicine. ⁶²	Lu Y...Shi H	36246960	2022
9	The Degree of Menstrual Disturbance Is Associated With the Severity of Insulin Resistance in PCOS. ⁶²	Li X...Zhao X	35769085	2022
10	Effect of glucose metabolism disorders on the short-term prognosis in neonates with asphyxia: a multicenter study in Hubei Province, China. ⁶²	Liu CH...Xia SW	34911602	2021
11	Maternal Metabolites Associated With Gestational Diabetes Mellitus and a Postpartum Disorder of Glucose Metabolism. ⁶²	Liu Y...Lowe WL	34255031	2021
12	Associations of urinary carbon disulfide metabolite with oxidative stress, plasma glucose and risk of diabetes among urban adults in China. ⁶²	Xu T...Chen W	33250290	2021
13	Diabetes is not (only) a disorder of glucose metabolism! ⁶²	Fanni G	33230859	2021
14	Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways. ⁶²	Ren BC...Li XY	32961025	2020
15	Fanconi-Bickel syndrome in a Ugandan child - diagnostic challenges in resource-limited settings: a case report. ⁶²	Piloya T...Musiime V	32993803	2020
16	The metabolic changes in the hippocampus of an atherosclerotic rat model and the regulation of aerobic training. ⁶²	Liu B...Lou S	32240489	2020
17	Astaxanthin Encapsulated in Biodegradable Calcium Alginate Microspheres for the Treatment of Hepatocellular Carcinoma In Vitro. ⁶²	Zhang X...He G	31811643	2020
18	The Role of PPARδ Agosnist GW501516 in Rats with Gestational Diabetes Mellitus. ⁶²	Zhou J...Wang Z	32669864	2020
19	Effect of sidt2 Gene on Cell Insulin Resistance and Its Molecular Mechanism. ⁶²	Xiong QY...Gao JL	32964053	2020
20	Diabetic Neuropathy. ⁶²	Zakin E...Simpson DM	31639839	2019
21	Glucose metabolic alterations in hippocampus of diabetes mellitus rats and the regulation of aerobic exercise. ⁶²	Li J...Lou S	29113873	2019
22	[Compound traditional Chinese medicine in treatment of diabetes]. ⁶²	Wu QH...Tu J	30989971	2019
23	PREGNANCY OUTCOME IN GESTATIONAL DIABETES COMPARED TO BODY MASS INDEX. ⁶²	Sabolovic Rudman S...Kosec V	31363323	2019
24	Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. ⁶²	Dale DC...Weinstein DA	30451720	2019
25	Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. ⁶²	Imai K...Shimizu M	30704150	2019
26	Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. ⁶²	Lowe WL...HAPO Follow-up Study Cooperative Research Group	30208453	2018
27	Takotsubo cardiomyopathy: FDG myocardial uptake pattern in fasting patients. Comparison of PET/CT, SPECT, and ECHO results. ⁶²	Kobylecka M...Krolicki L	28054182	2018
28	Susceptible and Prognostic Genetic Factors Associated with Diabetic Peripheral Neuropathy: A Comprehensive Literature Review. ⁶²	Prabodha LBL...Dissanayake VHW	29736170	2018
29	Recent Updates on Novel Approaches in Insulin Drug Delivery: A Review of Challenges and Pharmaceutical Implications. ⁶²	Pandey M...Hussain Z	29792143	2018
30	Oral Insulin: Myth or Reality. ⁶²	Kumar V...Jain D	28637407	2018
31	Incorporating Oral Health as Part of Routine Diabetes Care in Ireland. ⁶²	Ahern J...Nunn J	29465850	2017
32	In vitro and in silico interaction of porcine α-amylase with Vicia faba crude seed extract and evaluation of antidiabetic activity. ⁶²	Choudhary DK...Mishra A	27791455	2017
33	[Piperine regulates glucose metabolism disorder in HepG2 cells of insulin resistance models via targeting upstream target of AMPK signaling pathway]. ⁶²	Wan CP...Bao ZR	28952262	2017
34	[Management of hyperglycemic/diabetic patient during and in the immediate follow-up of an acute coronary syndrome]. ⁶²	Verges B	27374266	2016
35	[Posttransplantation diabetes mellitus in patients after kidney transplantation - Incidence and risk factors]. ⁶²	Jahn I...Battefeld W	27642745	2016
36	Oxidative Stress-Activated NHE1 Is Involved in High Glucose-Induced Apoptosis in Renal Tubular Epithelial Cells. ⁶²	Wu Y...Zhao C	27401659	2016
37	[Disorder of glucose metabolism (hypoglycemia, hyperglycemia)]. ⁶²	Takimoto R	25831798	2015
38	Costus afer Possesses Carbohydrate Hydrolyzing Enzymes Inhibitory Activity and Antioxidant Capacity In Vitro. ⁶²	Tchamgoue AD...Agbor GA	26246844	2015
39	Detection of diabetic metabolism disorders post-mortem--forensic case reports on cause of death hyperglycaemia. ⁶²	Hess C...Madea B	23620079	2013
40	Modes of inhibition of α -amylase and α -glucosidase by aqueous extract of Morinda lucida Benth leaf. ⁶²	Kazeem MI...Ogunwande IA	24455701	2013
41	[Research progress of effect of anti-diabetic traditional Chinese medicines based on regulation of glucose metabolic enzyme]. ⁶²	Ji L...Peng JY	23477131	2012
42	Diabetes: glycaemic control in type 2 (drug treatments). ⁶²	Gorter KJ...Rutten GE	23862772	2012
43	[The insulin regulation of metabolism of fat acids and glucose next in the realization of biologic function of locomotion]. ⁶²	Titov VN	22834149	2012
44	The usefulness of glycated hemoglobin A1c (HbA1c) for identifying dysglycemic states in individuals without previously diagnosed diabetes. ⁶²	Adamska E...Gorska M	22968341	2012
45	Continuous glucose monitoring by means of mid-infrared transmission laser spectroscopy in vitro. ⁶²	Vrancic C...Petrich W	21274463	2011
46	Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report. ⁶²	Taglietti F...Petrosillo N	20964809	2010
47	Inflammation and insulin resistance: an old story with new ideas. ⁶²	Kim JK	20617073	2010
48	An association between stress-induced disruption of the hypothalamic-pituitary-adrenal axis and disordered glucose metabolism in an animal model of post-traumatic stress disorder. ⁶²	Cohen H...Kaplan Z	19732290	2009
49	Normal and abnormal maternal metabolism during pregnancy. ⁶²	Hadden DR...McLaughlin C	18986856	2009
50	Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders? ⁶²	Melis D...Andria G	18437526	2008

Sources

Genes for Glucose Metabolism Disease

Genes related to Glucose Metabolism Disease (0 elite genes):

(show top 50) (show all 114)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PINK1-AS	PINK1 Antisense RNA	RNA Gene	153.12	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	22817756
2	MIR199A1	MicroRNA 199a-1	RNA Gene	14.75	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
3	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	12.53	DISEASES inferred ¹⁴ ¹⁴
4	MIR21	MicroRNA 21	RNA Gene	12.51	DISEASES inferred ¹⁴ ¹⁴
5	H2AC18	H2A Clustered Histone 18	Protein Coding	12.25	DISEASES inferred ¹⁴ ¹⁴
6	MIR126	MicroRNA 126	RNA Gene	12.25	DISEASES inferred ¹⁴ ¹⁴
7	INS	Insulin	Protein Coding	12	DISEASES inferred ¹⁴
8	SERPINA3	Serpin Family A Member 3	Protein Coding	11.54	DISEASES inferred ¹⁴ ¹⁴
9	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	11.34	DISEASES inferred ¹⁴ ¹⁴
10	MIR17	MicroRNA 17	RNA Gene	11.1	DISEASES inferred ¹⁴ ¹⁴
11	MIR146A	MicroRNA 146a	RNA Gene	11.1	DISEASES inferred ¹⁴ ¹⁴
12	MIR142	MicroRNA 142	RNA Gene	11.04	DISEASES inferred ¹⁴ ¹⁴
13	MIR223	MicroRNA 223	RNA Gene	11.02	DISEASES inferred ¹⁴ ¹⁴
14	MIR155	MicroRNA 155	RNA Gene	10.97	DISEASES inferred ¹⁴ ¹⁴
15	MIR29A	MicroRNA 29a	RNA Gene	10.87	DISEASES inferred ¹⁴ ¹⁴
16	MIR423	MicroRNA 423	RNA Gene	10.62	DISEASES inferred ¹⁴ ¹⁴
17	MIR140	MicroRNA 140	RNA Gene	10.54	DISEASES inferred ¹⁴ ¹⁴
18	MIR210	MicroRNA 210	RNA Gene	10.53	DISEASES inferred ¹⁴ ¹⁴
19	MIR144	MicroRNA 144	RNA Gene	10.48	DISEASES inferred ¹⁴ ¹⁴
20	GCG	Glucagon	Protein Coding	10.43	DISEASES inferred ¹⁴
21	MIR483	MicroRNA 483	RNA Gene	10.35	DISEASES inferred ¹⁴ ¹⁴
22	MIR27A	MicroRNA 27a	RNA Gene	10.34	DISEASES inferred ¹⁴ ¹⁴
23	MIR30A	MicroRNA 30a	RNA Gene	10.31	DISEASES inferred ¹⁴ ¹⁴
24	MIR486-1	MicroRNA 486-1	RNA Gene	10.25	DISEASES inferred ¹⁴ ¹⁴
25	LEP	Leptin	Protein Coding	10.2	DISEASES inferred ¹⁴
26	CRP	C-Reactive Protein	Protein Coding	10.19	DISEASES inferred ¹⁴
27	MIR23A	MicroRNA 23a	RNA Gene	10.18	DISEASES inferred ¹⁴ ¹⁴
28	MIR28	MicroRNA 28	RNA Gene	10.17	DISEASES inferred ¹⁴ ¹⁴
29	ADIPOQ	Adiponectin, C1Q And Collagen Domain Containing	Protein Coding	10.16	DISEASES inferred ¹⁴
30	ALB	Albumin	Protein Coding	10.14	DISEASES inferred ¹⁴
31	MIR22	MicroRNA 22	RNA Gene	10.12	DISEASES inferred ¹⁴ ¹⁴
32	MIR34A	MicroRNA 34a	RNA Gene	10.11	DISEASES inferred ¹⁴ ¹⁴
33	MIR342	MicroRNA 342	RNA Gene	10.09	DISEASES inferred ¹⁴ ¹⁴
34	MIR150	MicroRNA 150	RNA Gene	10.09	DISEASES inferred ¹⁴ ¹⁴
35	MIR122	MicroRNA 122	RNA Gene	10.06	DISEASES inferred ¹⁴ ¹⁴
36	MIR125A	MicroRNA 125a	RNA Gene	10.05	DISEASES inferred ¹⁴ ¹⁴
37	IL6	Interleukin 6	Protein Coding	10.03	DISEASES inferred ¹⁴
38	MIR143	MicroRNA 143	RNA Gene	9.97	DISEASES inferred ¹⁴ ¹⁴
39	MIR192	MicroRNA 192	RNA Gene	9.96	DISEASES inferred ¹⁴ ¹⁴
40	MIR181A1	MicroRNA 181a-1	RNA Gene	9.91	DISEASES inferred ¹⁴ ¹⁴
41	MIR221	MicroRNA 221	RNA Gene	9.87	DISEASES inferred ¹⁴ ¹⁴
42	MIR146B	MicroRNA 146b	RNA Gene	9.87	DISEASES inferred ¹⁴ ¹⁴
43	ACE	Angiotensin I Converting Enzyme	Protein Coding	9.85	DISEASES inferred ¹⁴
44	MIRLET7D	MicroRNA Let-7d	RNA Gene	9.82	DISEASES inferred ¹⁴ ¹⁴
45	MIR124-1	MicroRNA 124-1	RNA Gene	9.81	DISEASES inferred ¹⁴ ¹⁴
46	MIR93	MicroRNA 93	RNA Gene	9.81	DISEASES inferred ¹⁴ ¹⁴
47	TNF	Tumor Necrosis Factor	Protein Coding	9.81	DISEASES inferred ¹⁴
48	MIR9-1	MicroRNA 9-1	RNA Gene	9.77	DISEASES inferred ¹⁴ ¹⁴
49	MIR145	MicroRNA 145	RNA Gene	9.76	DISEASES inferred ¹⁴ ¹⁴
50	PPARG	Peroxisome Proliferator Activated Receptor Gamma	Protein Coding	9.74	DISEASES inferred ¹⁴

Sources

Variations for Glucose Metabolism Disease

Sources

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Sources

Pathways for Glucose Metabolism Disease

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.46	MIR223 MIR199A1 MIR17 MIR155
2	miRNAs involvement in the immune response in sepsis ⁷⁴	11.25	MIR21 MIR199A1 MIR155 MIR126
3	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	10.94	MIR29A MIR210 MIR21 MIR146A
4	miRNAs involved in DNA damage response ⁷⁴	10.85	MIR29A MIR223 MIR210 MIR21 MIR17

Sources

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.91	SERPINA3 MIR423 MIR29A MIR223 MIR210 MIR21
2	RISC complex	GO:0016442	9.74	MIR126 MIR140 MIR142 MIR144 MIR146A MIR155
3	extracellular vesicle	GO:1903561	9.46	MIR29A MIR21 MIR17 MIR126

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.09	INS MIR140 MIR144 MIR146A MIR17 MIR21
2	cellular response to lipopolysaccharide	GO:0071222	9.93	MIR223 MIR21 MIR17 MIR146A MIR140
3	positive regulation of protein kinase B signaling	GO:0051897	9.93	MIR29A MIR21 MIR199A1 MIR126 INS
4	positive regulation of angiogenesis	GO:0045766	9.91	MIR29A MIR210 MIR21 MIR199A1 MIR126
5	cellular response to hypoxia	GO:0071456	9.88	MIR17 MIR146A MIR140 MIR126
6	negative regulation of inflammatory response	GO:0050728	9.88	MIR223 MIR199A1 MIR146A MIR142 MIR126
7	negative regulation of gene expression	GO:0010629	9.85	MIR29A MIR21 MIR199A1 MIR17 MIR155 MIR146A
8	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.77	MIR21 MIR17 MIR146A
9	negative regulation of NIK/NF-kappaB signaling	GO:1901223	9.74	MIR223 MIR21 MIR146A
10	positive regulation of vascular endothelial cell proliferation	GO:1905564	9.72	MIR29A MIR21 MIR126
11	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.7	MIR140 MIR21 MIR223
12	miRNA-mediated gene silencing	GO:0035195	9.68	MIR423 MIR29A MIR223 MIR210 MIR21 MIR199A1
13	positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903589	9.67	MIR21 MIR146A MIR126
14	miRNA-mediated gene silencing by mRNA destabilization	GO:0035279	9.62	MIR223 MIR210 MIR146A MIR140
15	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.59	MIR199A1 MIR17
16	positive regulation of metalloendopeptidase activity	GO:1904685	9.58	MIR21 MIR17
17	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.58	MIR210 MIR21 MIR17
18	negative regulation of matrix metallopeptidase secretion	GO:1904465	9.56	MIR199A1 MIR146A
19	negative regulation of vascular endothelial growth factor production	GO:1904046	9.56	MIR199A1 MIR17 MIR146A MIR140
20	negative regulation of BMP secretion	GO:2001285	9.54	MIR210 MIR17 MIR140
21	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.5	MIR126 MIR144 MIR146A MIR17 MIR21 MIR210

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.73	MIR29A MIR223 MIR210 MIR21 MIR199A1 MIR17
2	mRNA base-pairing translational repressor activity	GO:1903231	9.44	MIR423 MIR29A MIR223 MIR210 MIR21 MIR199A1